We aimed to investigate plasma NDEV levels of core pathological markers (Aβ42, P‐T181‐tau, and P‐S396‐tau) and inflammatory biomarkers, including interleukin 6 (IL‐6) and matrix metalloproteinase‐9 (MMP‐9) in AD patients. This evidence concerns the gene MAPT and Alzheimer disease.